Moreover, CD8+ T cells can trigger ACSL4-dependent tumor ferroptosis by utilizing IFN-γ and arachidonic acid, thus elevating ICB cancer immunotherapy [17,36,37]. This evidence concerns the gene CD8A and neoplasm.